The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer
Abstract
Purpose Dosimetry is critical to achieve the optimal therapeutic effect of radioligand therapy (RLT) with limited side effects. Our aim was to perform image-based absorbed dose calculation for the new PSMA ligand (177)Lu-DKFZ-PSMA-617 in support of its use for the treatment of metastatic prostate cancer.Methods Whole-body planar images and SPECT/CT images of the abdomen were acquired in five patients (mean age 68 years) for during two treatment cycles at approximately 1, 24, 48 and 72 h after administration of 3.6 GBq (range 3.4 to 3.9 GBq) (177)Lu-DKFZ-PSMA-617. Quantitative 3D SPECT OSEM reconstruction was performed with corrections for photon scatter, photon attenuation and detector blurring. A camera-specific calibration factor derived from phantom measurements was used for quantitation. Absorbed doses were calculated for various organs from the images using a combination of linear approximation, exponential fit, and target-specific S values, in accordance with the MIRD scheme. Absorbed doses to bone marrow were estimated from planar and SPECT images and with consideration of the blood sampling method according to the EANM guidelines.Results The average (± SD) absorbed doses per cycle were 2.2 ± 0.6 Gy for the kidneys (0.6 Gy/GBq), 5.1 ± 1.8 Gy for the salivary glands (1.4 Gy/GBq), 0.4 ± 0.2 Gy for the liver (0.1 Gy/GBq), 0.4 ± 0.1 Gy for the spleen (0.1 Gy/GBq), and 44 ± 19 mGy for the bone marrow (0.012 Gy/GBq). The organ absorbed doses did not differ significantly between cycles. The critical absorbed dose reported for the kidneys (23 Gy) was not reached in any patient. At 24 h there was increased uptake in the colon with 50 - 70 % overlap to the kidneys on planar images. Absorbed doses for tumour lesions ranged between 1.2 and 47.5 Gy (13.1 Gy/GBq) per cycle.Conclusion The salivary glands and kidneys showed high, but not critical, absorbed doses after RLT with (177)Lu-DKFZ-PSMA-617. We suggest that (177)Lu-DKFZ-PSMA-617 is suitable for radiotherapy, offering tumour-to-kidney ratios comparable to those with RLT agents currently available for the treatment of neuroendocrine tumours. Our dosimetry results suggest that (177)Lu-DKFZ-PSMA-617 treatment with higher activities and more cycles is possible without the risk of damaging the kidneys.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Delker et al. estimated a mean of 1.4 Gy/GBq to the salivary glands from 177 Lu-PSMA-617 therapies ( 77 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [77]
Citations
Cites
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Tolerance of normal tissue to therapeutic irradiation
Emami, B., Lyman, J., Brown, A., Cola, L., Goitein, M., Munzenrider, J. E., Shank, B., Solin, L. J., & Wesson, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90171-y · Cited by 4,488
Accelerated image reconstruction using ordered subsets of projection data
Hudson, H. M., & Larkin, R. S. (1994) · IEEE Transactions on Medical Imaging · doi:10.1109/42.363108 · Cited by 3,713
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
(1997) · PubMed · Cited by 1,541
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L. R., van Eijck, C. H. J., van Essen, M., Kooij, P. P. M., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,454
Bayesian reconstructions from emission tomography data using a modified EM algorithm
Green, P. J. (1990) · IEEE Transactions on Medical Imaging · doi:10.1109/42.52985 · Cited by 1,242
Afshar‐Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H., Hadaschik, B. A., Holland‐Letz, T., Giesel, F. L., Kratochwil, C., Haufe, S., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2298-2 · Cited by 919
Self-citationTumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
Ghosh, A., & Heston, W. D. W. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10661 · Cited by 883
Zaknun, J. J., Bodei, L., Mueller‐Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O'Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 837
Benešová, M., Schäfer, M. K.-H., Bauder‐Wüst, U., Afshar‐Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147413 · Cited by 621
Self-citationBander, N. H., Milowsky, M. I., Nanus, D. M., Kostakoğlu, L., Vallabhajosula, S., & Goldsmith, S. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.160 · Cited by 511
Tagawa, S. T., Milowsky, M. I., Morris, M. J., Vallabhajosula, S., Christos, P. J., Akhtar, N. H., Osborne, J. R., Goldsmith, S. J., Larson, S. M., Taskar, N. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0231 · Cited by 427
Dewaraja, Y. K., Frey, E. C., Sgouros, G., Brill, A. B., Roberson, P. L., ZANZONICO, P. B., & Ljungberg, M. H. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.100123 · Cited by 419
Zechmann, C. M., Afshar‐Oromieh, A., Armor, T., Stubbs, J. B., Mier, W., Hadaschik, B. A., Joyal, J. L., Kopka, K., Debus, J., Babich, J. W., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2713-y · Cited by 359
Self-citationMIRD Pamphlet No. 24: Guidelines for Quantitative 131I SPECT in Dosimetry Applications
Dewaraja, Y. K., Ljungberg, M. H., Green, A. J., ZANZONICO, P. B., Frey, E. C., Bolch, W. E., Brill, A. B., Dunphy, M. P., Fisher, D. R., Howell, R. W., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.122390 · Cited by 335
PHYSICAL MODELS AND DOSE FACTORS FOR USE IN INTERNAL DOSE ASSESSMENT
Stabin, M. G., & Siegel, J. A. (2003) · Health Physics · doi:10.1097/00004032-200309000-00006 · Cited by 314
Milowsky, M. I., Nanus, D. M., Kostakoğlu, L., Vallabhajosula, S., Goldsmith, S. J., & Bander, N. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.154 · Cited by 313
EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry
Hindorf, C., Glatting, G., Chiesa, C., Lindén, O., & Flux, G. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1422-4 · Cited by 300
Bone marrow dosimetry for radioimmunotherapy: theoretical considerations.
Sgouros, G. (1993) · PubMed · Cited by 298
Sandström, M., Garske‐Román, U., Granberg, D. O., Johansson, S., Widström, C., Eriksson, B. K., Sundin, A., Lundqvist, H., & Lubberink, M. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.107524 · Cited by 287
Wild, D., Fani, M., Fischer, R., Pozzo, L. D., Kaul, F., Krebs, S. S., Fischer, R., Rivier, J., Reubi, J. C., Maëcke, H. R., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.138834 · Cited by 267
Lutetium-labelled peptides for therapy of neuroendocrine tumours
Kam, B. L. R., Teunissen, J. J. M., Krenning, E. P., de Herder, W. W., Khan, S., van Vliet, E. I., & Kwekkeboom, D. J. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2039-y · Cited by 247
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
Forrer, F., Krenning, E. P., Kooij, P. P. M., Bernard, B. F., Konijnenberg, M., Bakker, W. H., Teunissen, J. J. M., de Jong, M., van Lom, K., de Herder, W. W., et al. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1072-6 · Cited by 204
Pond, G. R., Sonpavde, G., de Wit, R., Eisenberger, M. A., Tannock, I. F., & Armstrong, A. J. (2014) · European Urology · doi:10.1016/j.eururo.2013.09.024 · Cited by 193
Vallabhajosula, S., Kuji, I., Hamacher, K. A., Konishi, S., Kostakoğlu, L., Kothari, P. A., Milowsky, M. I., Nanus, D. M., Bander, N. H., & Goldsmith, S. J. (2005) · PubMed · Cited by 129
A generalized model for the conversion from CT numbers to linear attenuation coefficients
Bai, C., Shao, L., Silva, A. J. D., & Zhao, Z. (2003) · IEEE Transactions on Nuclear Science · doi:10.1109/tns.2003.817281 · Cited by 125
Scatter compensation methods in 3D iterative SPECT reconstruction: A simulation study
Beekman, F. J., Kamphuis, C., & Frey, E. C. (1997) · Physics in Medicine and Biology · doi:10.1088/0031-9155/42/8/011 · Cited by 106
Prostate-specific membrane antigen expression in regeneration and repair
Gordon, I. O., Tretiakova, M., Noffsinger, A. E., Hart, J. A. L., Reuter, V. E., & Al‐Ahmadie, H. A. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.143 · Cited by 89
Hey, J., Setz, J. M., Gerlach, R., Janich, M., Hildebrandt, G., Vordermark, D., Gernhardt, C. R., & Kuhnt, T. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-125 · Cited by 72
Minor changes in effective half-life during fractionated 177 Lu-Octreotate therapy
Garske, U., Sandström, M., Johansson, S., Sundin, A., Granberg, D. O., Eriksson, B. K., & Lundqvist, H. (2011) · Acta Oncologica · doi:10.3109/0284186x.2011.618511 · Cited by 67
Sanders, J. C., Kuwert, T., Joachim Hornegger, A., & Ritt, P. (2014) · Molecular Imaging and Biology · doi:10.1007/s11307-014-0806-4 · Cited by 64
An optimal rotator for iterative reconstruction
Wallis, J. W., & Miller, T. R. (1997) · IEEE Transactions on Medical Imaging · doi:10.1109/42.552061 · Cited by 59
Yttrium-labelled peptides for therapy of NET
Bodei, L., Cremonesi, M., Grana, C. M., Chinol, M., Baio, S. M., Severi, S., & Paganelli, G. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2002-y · Cited by 55
Traino, C., Ferrari, M. E., Cremonesi, M., & Stabin, M. G. (2007) · Physics in Medicine and Biology · doi:10.1088/0031-9155/52/17/009 · Cited by 51
Gensheimer, M. F., Liao, J. J., Garden, A. S., Laramore, G. E., & Parvathaneni, U. (2014) · Radiation Oncology · doi:10.1186/s13014-014-0255-x · Cited by 44
Delker, A., Ilhan, H., Zach, C., Brosch-Lenz, J., Gildehaus, F. J., Lehner, S., Bartenstein, P., & Böning, G. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0839-3 · Cited by 41
Self-citationKohli, V., King, M. A., Glick, S. J., & Pan, T.-S. (1998) · Physics in Medicine and Biology · doi:10.1088/0031-9155/43/4/029 · Cited by 37
Larson, S. M., Raubitschek, A. A., Reynolds, J. C., Neumann, R. D., Hellström, K. E., Hellström, I., Colcher, D. M., Schlom, J., GLATSTEIN, E. J., & Carrasquillo, J. A. (1989) · International Journal of Radiation Applications and Instrumentation Part B Nuclear Medicine and Biology · doi:10.1016/0883-2897(89)90188-8 · Cited by 23
Maraj, B. H., Aldersley, M. A., & Markham, A. F. (1998) · The Lancet · doi:10.1016/s0140-6736(05)61125-7 · Cited by 15
The two types of correction of absorbed dose estimates for internal emitters
Williams, L. E., Liu, A., Yamauchi, D. M., Lopatin, G., Raubitschek, A. A., & Wong, J. Y. C. (2002) · Cancer · doi:10.1002/cncr.10290 · Cited by 12
I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
Zechmann, C. M., Afshar‐Oromieh, A., Armor, T., Stubbs, J. B., Mier, W., Hadaschik, B. A., Joyal, J. L., Kopka, K., Debus, J., Babich, J. W., et al. (2014) · Cited by 10
Self-citation
Research works printed but not linked: 1
- Siegel J, Wessels B, Watson E, Stabin M, Vriesendorp H, Bradley E, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconjug Radiopharm. 1990;3:213–34.
Cited by
Sorted by citations
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,187
Self-citationKratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Self-citationCurrent use of PSMA–PET in prostate cancer management
Maurer, T., Eiber, M. J., Schwaiger, M., & Gschwend, J. E. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.26 · Cited by 613
Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505
Self-citationViolet, J., Jackson, P., Ferdinandus, J., Sandhu, S., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Thang, S. P., Eu, P., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219352 · Cited by 504
Metadata
- Authors
- Delker, A., Fendler, W. P., Kratochwil, C., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., Tritschler, S., Stief, C. G., Kopka, K., Haberkorn, U., Bartenstein, P., & Böning, G.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- University Hospital Heidelberg (DE)
- German Cancer Research Center (DE)
- Corresponding author
- Böning, Guido
- ORCID
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2015-08-29
- Volume
- 43
- Issue
- 1
- Pages
- 42-51
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W1140456871
- Cited by
- 322
- References
- 42
- Citations by year
- 2026: 16 · 2025: 20 · 2024: 23 · 2023: 21 · 2022: 31 · 2021: 51 · 2020: 41 · 2019: 33 · 2018: 32 · 2017: 27 · 2016: 26 · 2015: 1
- FWCI
- 23.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Deutschen Konsortium für Translationale Krebsforschung
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Physical Sciences › Physics and Astronomy › Radiation › Advanced Radiotherapy Techniques
- Keywords
- radioligand therapy, dosimetry, absorbed dose, metastatic prostate cancer, PSMA ligands, SPECT/CT, kidney dose, salivary gland dose, bone marrow dose, critical organ dose, tumor dose, EANM guidelines
- MeSH terms
- Aged, Aged, 80 and over, Antigens, Surface, Humans, Male, Middle Aged, Neoplasm Metastasis, Organometallic Compounds, Peptides, Radiometry, Radiopharmaceuticals, Glutamate Carboxypeptidase II, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
